Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IONIS MAPTRx · ISIS 814907

Oligonucleotide (Antisense oligonucleotide) · developed by Ionis Pharmaceuticals

Phase 1 Most advanced trial (none active)

IONS Developer

1 Registered trials

What is IONIS MAPTRx?

IONIS MAPTRx (ISIS 814907) is an antisense oligonucleotide in development for mild Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ISIS 814907
Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Neurology
Developer: Ionis Pharmaceuticals, Inc. (IONS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03186989	Phase 1	Mild Alzheimer's Disease	Completed	IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mild Alzheimer's Disease

More from Ionis Pharmaceuticals

Donidalorsen FDA approved Olezarsen FDA approved Zilganersen FDA approved BIIB094 Phase 1 ION224 Phase 2 ION269 Phase 1 ION337 Phase 1/2 ION356 Phase 1 ION363 Phase 3 ION440 Phase 1/2 ION464 Phase 1 ION717 Phase 1/2

Follow IONS, the company behind IONIS MAPTRx

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z